About
This formulation combines incretin-based metabolic therapies used in weight management and metabolic health programs. Semaglutide acts as a GLP-1 receptor agonist, while Tirzepatide activates both GLP-1 and GIP receptors, helping regulate appetite, improve insulin signaling, and support glucose metabolism. Together they support appetite control and metabolic balance in individuals with obesity or insulin resistance.

Key Benefits

• Supports appetite regulation and reduced caloric intake
• Improves glucose metabolism and insulin sensitivity
• Helps support weight management and fat reduction
• Supports improved metabolic control and glycemic balance
• May assist with reduction of cardiometabolic risk factors

Administration
Subcutaneous injection.

Typical Clinical Use
Commonly used in weight management programs, metabolic optimization protocols, insulin resistance management, and obesity treatment strategies.